News of Note—Teva accused of shortcutting plant sale; Sun plant gets only one observation

newspapers
(Pixabay)

> Teva has been sued by an Israeli businessman who claims his bid for the land use for two plants the drugmaker is closing in Jerusalem was overlooked. Story

> Sun Pharmaceutical has received on observation during a January FDA inspection of its plant in Halol. Form 483 (PDF)

> Strides says the FDA has approved a new dosage plant in Singapore. Filing (PDF)

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

> Shanghai-based WuXi STA has received EMA approval for a new drug product manufacturing facility in the Waigaoqiao Free Trade Zone of Shanghai. Release

> Lupin has received EU approval for a biologics plant in India. Story

> Cambrex says it has doubled the liquid filling capacity at its plant in Mirabel, Québec. Release

 

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.